Press Releases

Biopharma clinical development veteran to propel Opus’ AAV-based gene therapies for inherited retinal diseases toward patients

Research Triangle Park, N.C. – May 11, 2022 – Opus Genetics, a patient-focused gene therapy company developing treatments for inherited retinal diseases, today announced the appointment of Jennifer Hunt as Chief Development Officer (CDO). In this role, Hunt will lead clinical development and regulatory affairs, responsible for progressing and expanding Opus’ AAV-based gene therapy pipeline which currently includes preclinical candidates OPGx-001, OPGx-002 and OPGx-003 to address forms of Leber congenital amaurosis (LCA) due to mutations of LCA5, RDH12 and NMNAT1 genes, respectively.

“We’re pleased to welcome Jennifer at this exciting time for Opus, as we build out the team that will be foundational to realizing our mission to efficiently advance therapies for inherited retinal diseases,” Ben Yerxa, Ph.D., CEO of the Foundation Fighting Blindness and the Retinal Degeneration Fund, and acting CEO of Opus. “Jennifer’s deep clinical development background and experience overseeing trials in rare diseases and LCA will be instrumental as we progress our current programs toward the patients that need these therapies.”

Hunt brings over 25 years of drug development experience to Opus, with specific expertise in global clinical operations, product development and program management in biologics, small molecules, gene editing and gene therapy. Prior to joining Opus, she held key clinical and regulatory positions at several biopharmaceutical companies, including Genzyme, Voyager Therapeutics and Editas Medicine. While at Editas, she oversaw the development of CRISPR medicines across ophthalmology, hemoglobinopathies and oncology, including Editas’ gene therapy to restore vision loss in patients with LCA type 10, the first in-vivo CRISPR IND ever accepted by the U.S. Food and Drug Administration.

“I am inspired by Opus’ passionate commitment to patient need,” said Hunt. “Opus is in a strong position to advance multiple therapies for inherited retinal diseases. I’m looking forward to leveraging my experience to tackle some of the most neglected forms of inherited blindness and make a difference in the lives of patients.”

Hunt earned a B.S. in Biology from State University of New York College of Environmental Science and Forestry at Syracuse and a M.S. in Management from Lesley University.

About Opus Genetics

Opus Genetics is a groundbreaking gene therapy company for inherited retinal diseases with a unique model and purpose. Backed by Foundation Fighting Blindness’s venture arm, the RD Fund, Opus combines unparalleled insight and commitment to patient need with wholly owned programs in numerous orphan retinal diseases. Its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. Based in Research Triangle Park, N.C., the company leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. For more information, visit www.opusgenetics.com.

Media Contact:
Heather Anderson
6 Degrees
919-827-5539
handerson@6degreespr.com

Retinal regions of preserved photoreceptors identified as targets for subretinal delivery of AAV8-based gene therapy to address mutations in genes that cause forms of Leber congenital amaurosis

Subretinal injection well tolerated in preclinical dose-ranging studies

Data presented at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2022 

Research Triangle Park, N.C. – May 4, 2022 – Opus Genetics, a patient-focused gene therapy company developing treatments for inherited retinal diseases, today announced promising new preclinical data from studies evaluating the potential of its gene therapies OPGx-001 and OPGx-002 to address forms of Leber congenital amaurosis (LCA), a group of rare inherited retinal diseases characterized by photoreceptor degeneration, due to mutations of LCA5 or RDH12 genes, respectively.

In preparation for IND-enabling trials of OPGx-001 and OPGx-002, studies were conducted to determine eligibility, therapeutic window, and possible outcome measures for gene therapy for LCA5 and RDH12 inherited retinal diseases. In addition, safety evaluations for the subretinal delivery of an AAV8 vector containing LCA5 or RDH12 were performed in non-human primates (NHP).

The data demonstrated that despite severe retinal dysfunction, LCA patients exhibited detectable photoreceptor regions that may be targets for gene augmentation, identified in the central and midperipheral retina of LCA5-LCA patients and in the pericentral and peripapillary retina of RDH12-LCA patients. In two dose-ranging studies in NHPs, subretinal delivery of OPGx-001 and OPGx-002 was well tolerated, with mild inflammatory changes observed at the higher dose. The data support the therapeutic potential and tolerability of gene augmentation to address LCA5-LCA and RDH12-LCA and provide guidance for formal preclinical toxicology studies and future human clinical trials.

“Patients with Leber congenital amaurosis due to mutations of the LCA5 or RDH12 genes experience rapid retinal degeneration, resulting in vision loss in early childhood,” said Ash Jayagopal, Ph.D., Chief Scientific Officer of Opus. “The detection of preserved photoreceptors in LCA patients signals a therapeutic opportunity to target the mutation and potentially restore structure and function through gene augmentation. In addition, the encouraging dose-ranging results in the primate model suggest subretinal delivery of Opus’ AAV8-based gene therapies are safe and inform the doses to be used in our toxicology studies, a key step on our path toward the clinic for OPGx-001 and OPGx-002.”

The data were presented today at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2022 in Denver, Colo., by Jean Bennett, M.D., Ph.D., Scientific Co-founder, Opus Genetics, and University of Pennsylvania Perelman School of Medicine; and Tomas Aleman, M.D., University of Pennsylvania Perelman School of Medicine.

Also at ARVO 2022, Dr. Jayagopal was awarded the title of ARVO Fellow, an honor established to recognize current ARVO members for their individual accomplishments, leadership and contributions to the ARVO Association.

About Opus Genetics

Opus Genetics is a groundbreaking gene therapy company for inherited retinal diseases with a unique model and purpose. Backed by Foundation Fighting Blindness’s venture arm, the RD Fund, Opus combines unparalleled insight and commitment to patient need with wholly owned programs in numerous retinal diseases. Its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel manufacturing scale and efficiencies. Based in Research Triangle Park, N.C., the company leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. For more information, visit www.opusgenetics.com.

Media Contact:
Heather Anderson
6 Degrees
919-827-5539
handerson@6degreespr.com

Data support the continued development of OPGx-001 and OPGx-002 to address mutations in genes causing forms of Leber congenital amaurosis

Raleigh, N.C. – April 28, 2022 – Opus Genetics, a patient-focused gene therapy company developing treatments for inherited retinal diseases, today announced that data from two preclinical studies evaluating the potential of its gene therapies OPGx-001 and OPGx-002 to address forms of Leber congenital amaurosis (LCA) due to mutations of LCA5 or RDH12 genes, respectively, will be presented in poster sessions at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2022, being held May 1-4, 2022, virtually and in Denver, Colo.

Details of the presentations are as follows:

Title: Preparation for a Gene Therapy Trial for LCA5-Associated Retinal Degenerations: Treatment Potential in Patients and Dose-ranging Studies in Non-human Primates

Session: Novel Animal Models and Neuroprotection in the Retina

Location: Virtual webcast

Date / time: Wednesday, May 4, 2022, 12:30-2:30 p.m. MDT

Presenter: Jean Bennett, M.D., Ph.D., Scientific Co-founder, Opus Genetics; Department of Ophthalmology, University of Pennsylvania Perelman School of Medicine

 

Title: Preparation for a Gene Augmentation Trial for RDH12-Associated Retinal Degenerations

Session: Retinal Degenerations, Gene Therapy, Transplantation, and Prostheses

Location: F0299, Denver Convention Center

Date / time: Wednesday, May 4, 2022, 3-5 p.m. MDT

Presenter: Tomas Aleman, M.D., Center for Advanced Retinal and Ocular Therapeutics (CAROT), Scheie Eye Institute, Department of Ophthalmology, University of Pennsylvania Perelman School of Medicine

The ARVO Annual Meeting is the premiere gathering for eye and vision scientists to share the latest research findings and collaborate on innovative solutions. For more information, visit https://www.arvo.org/annual-meeting/.

In addition, Ash Jayagopal, Ph.D., Chief Scientific Officer of Opus Genetics, will present a company overview, titled “Opus Genetics, a patient-centric biotech committed to developing ultrarare IRD therapies,” at the Foundation Fighting Blindness’ 7th Annual Retinal Cell and Gene Therapy Innovation Summit on Friday, April 29, 2022, at 10:20 a.m. MDT, in Denver, Colo. The annual summit, held prior to the ARVO Annual Meeting, features presentations by leading retinal disease experts on potential gene and stem-cell therapies and how best to deliver them to patients. For more information, visit https://www.fightingblindness.org/events/innovation-summit-2022-372.

About Opus Genetics

Opus Genetics is a groundbreaking gene therapy company for inherited retinal diseases with a unique model and purpose. Backed by Foundation Fighting Blindness’s venture arm, the RD Fund, Opus combines unparalleled insight and commitment to patient need with wholly owned programs in numerous retinal diseases. Its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel manufacturing scale and efficiencies. Based in Raleigh, N.C., the company leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. For more information, visit www.opusgenetics.com.

Media Contact:
Heather Anderson
919-827-5539

handerson@6degreespr.com

 Opus’ first-in-human trials to begin in 2022

Raleigh, N.C. – April 11, 2022 – Opus Genetics, a patient-focused gene therapy company developing treatments for inherited retinal diseases, today announced a strategic manufacturing services agreement with National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, to support the development and manufacturing of Opus’ pipeline.

Resilience will provide process and analytical development, quality control testing, and GMP manufacturing services for IND-enabling toxicology and first-in-human material for Opus’ adeno-associated viral (AAV) vector-based gene therapies for inherited retinal diseases (IRD) for use in both preclinical studies, and future clinical trials in the U.S. The work will be conducted at Resilience’s facilities in Waltham, Mass., and Research Triangle Park, N.C.

“Resilience embraces our innovative model to create a clinical manufacturing infrastructure that’s scaled to address rare inherited retinal diseases, and we are pleased to enter into this strategic collaboration,” said Ben Yerxa, Ph.D., CEO of the Foundation Fighting Blindness and the Retinal Degeneration Fund, and acting CEO of Opus. “Leveraging Resilience’s expertise puts Opus in the best position to efficiently advance our AAV-based gene therapies into the clinic and toward the patients who need them.”

“Helping Opus advance their gene therapies for inherited retinal diseases to the clinic will hopefully lead to new treatments for underserved patients,” said Rahul Singhvi, ScD, Chief Executive Officer of Resilience. “We’re excited to partner with Opus on process development and manufacturing at this pivotal time for the company.”

Opus’s lead program, OPGx-001, is designed to address mutations in the LCA5 gene, which encodes the lebercilin protein. Opus anticipates filing an IND and entering first-in-human trials with OPGx-001 this year. Opus’ earlier stage programs include OPGx-002, to restore protein expression and halting functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase (RDH12) gene, and OPGx-003, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 (NMNAT1) gene.

About Opus Genetics

Opus Genetics is a groundbreaking gene therapy company for inherited retinal diseases with a unique model and purpose. Backed by Foundation Fighting Blindness’s venture arm, the RD Fund, Opus combines unparalleled insight and commitment to patient need with wholly owned programs in numerous retinal diseases. Its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel manufacturing scale and efficiencies. Based in Raleigh, N.C., the company leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. For more information, visit www.opusgenetics.com.

Media Contact:
Heather Anderson
919-827-5539
handerson@6degreespr.com

20-year biopharma industry veteran to lead manufacturing for Opus’ AAV-based gene therapies for inherited retinal diseases

RALEIGH, N.C., Feb. 15, 2022 (GLOBE NEWSWIRE) — Opus Genetics, a patient-focused gene therapy company developing treatments for orphan inherited retinal diseases, today announced the appointment of Brian Leising as Vice President of Manufacturing.
Mr. Leising has over 20 years of gene therapy, vaccine and biopharmaceutical experience in manufacturing, quality, facility startup and process development roles across a variety of products in both the clinical and commercial stages. In his role, Mr. Leising will lead Opus’ efforts with key partners to manufacture IND-enabling GLP toxicology and first-in-human material to support the continued advancement of Opus’ portfolio toward clinical trials to address orphan inherited retinal diseases. Opus anticipates filing an IND and entering first-in-human trials with lead program OPGx-001 in LCA5 this year.

“Opus is building an engine to solve as many degenerative retinal diseases as possible, and manufacturing is a lynchpin of our success in efficiently advancing new therapies for rare inherited retinal diseases into the clinic,” said Ben Yerxa, Ph.D., CEO of the Foundation Fighting Blindness and the Retinal Degeneration Fund, and acting CEO of Opus. “Brian will be instrumental in the conceptualization and development of our manufacturing approach and we’re glad to have him on board as we work toward IND and our first-in-human trials later this year.”

Mr. Leising previously served as Director of Manufacturing Quality at Novartis Gene Therapies (formerly AveXis). In this role, he was responsible for implementation and oversight of the site quality systems for AAV gene therapy for the Durham facility startup, validation and licensure for Zolgensma, as well as for multiple clinical molecules. Prior to Novartis Gene Therapies, Mr. Leising was Director of Clinical Gene Therapy Manufacturing at Pfizer’s former Bamboo facility overseeing Phase 1 manufacturing of their AAV-based gene therapies and future clinical manufacturing infrastructure. Mr. Leising holds an M.S. in biotechnology from the University of Maryland and a B.S. in biology from the Florida Institute of Technology.

“Opus has an incredible opportunity to move strong and validated science and well-characterized material into the clinic expeditiously,” said Mr. Leising. “I’m thrilled to join Opus to help drive the development of a scalable, strategic manufacturing infrastructure that can be leveraged for IND, clinical and commercial stages, for multiple products.”

About Opus Genetics
Opus Genetics is a groundbreaking gene therapy company for inherited retinal diseases with a unique model and purpose. Backed by Foundation Fighting Blindness’s venture arm, the RD Fund, Opus combines unparalleled insight and commitment to patient need with wholly owned programs in numerous orphan retinal diseases. Its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. Based in Raleigh, N.C., the company leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. For more information, visit www.opusgenetics.com.

Media Contact:
Heather Anderson
919-827-5539
handerson@6degreespr.com

Program targets NMNAT1 gene based on the work of Opus scientific founder Dr. Eric Pierce

RALEIGH, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) — Opus Genetics, a patient-focused gene therapy company developing treatments for orphan inherited retinal diseases, today announced an agreement to license its third preclinical program to address mutations in the NMNAT1 gene, which cause a specific form of Leber congenital amaurosis (LCA), from Massachusetts Eye and Ear, the primary teaching hospital at Harvard Ophthalmology.

The new program, OPGx-003, is based on the work of Eric Pierce, M.D., Ph.D., Director of the Ocular Genomics Institute and William F. Chatlos Professor of Ophthalmology at Massachusetts Eye and Ear and Harvard Medical School, and scientific co-founder of Opus. OPGx-003 is a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 (NMNAT1) gene. Recent preclinical data have demonstrated the potential for this gene augmentation approach to achieve stable rescue of retinal structure and function. Opus expects to file an IND for OPGx-003 in the first half of 2023.

“We’re thrilled to collaborate with Dr. Pierce, who will bring his expertise in retinal gene therapy to researching a novel treatment of NMNAT1-associated retinal degeneration,” said Ash Jayagopal, Ph.D., Chief Scientific Officer of Opus Genetics. “Adding OPGx-003 to the Opus pipeline further underscores our commitment to bringing the required resources and expertise together to take promising science from the lab through the clinic and ultimately to patients who need it, and reinforces the importance of our innovative patient-focused model.”

“I’ve seen firsthand the need for new treatments for rare inherited retinal diseases,” said Dr. Pierce. “As someone who has devoted my life to research in this space, I believe strongly that Opus is an ideal company to advance this work to make a difference for patients in need.”

Opus’s lead program, OPGx-001, is designed to address mutations in the LCA5 gene, which encodes the lebercilin protein. The company’s second program, OPGx-002, will focus on restoring protein expression and halting functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase (RDH12) gene (LCA13).

About Opus Genetics
Opus Genetics is a groundbreaking gene therapy company for inherited retinal diseases with a unique model and purpose. Backed by Foundation Fighting Blindness’s venture arm, the RD Fund, Opus combines unparalleled insight and commitment to patient need with wholly owned programs in numerous orphan retinal diseases. Its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. Based in Raleigh, N.C., the company leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. For more information, visit www.opusgenetics.com.

Disclosures
Dr. Pierce holds equity in and serves as a consultant for Opus Genetics.

Media Contact:
Heather Anderson
919-827-5539
handerson@6degreespr.com

ALEIGH, N.C., Nov. 08, 2021 (GLOBE NEWSWIRE) — Opus Genetics, a patient-focused gene therapy company developing treatments for orphan inherited retinal diseases, today announced that Ben Yerxa, Ph.D., acting CEO of Opus and CEO of the Foundation Fighting Blindness and the Retinal Degeneration Fund, will deliver a company presentation at Eyecelerator@AAO 2021, on Thursday, November 11, 2021, in New Orleans.

Dr. Yerxa’s Opus presentation will be part of the Retina Spotlight: Meet the Game-Changing Innovators With the Most Promising Strategies For Impacting Retina session, which includes a panel and a diverse line-up of five companies presenting innovations at all stages in a unique, interactive format.

“We’re thrilled to be invited to introduce Opus and highlight our innovative model at Eyecelerator,” said Dr. Yerxa. “Created by the Foundation’s RD Fund, Opus emerged from stealth mode in September singularly focused on developing and manufacturing orphaned AAV-based gene therapies to treat neglected, orphan inherited retinal diseases. We look forward to showcasing our unique, patient-guided approach at this premiere industry event.”

Eyecelerator@AAO 2021 is ophthalmology’s next-generation business conference that brings together leading ophthalmic companies and important new startups for fresh perspectives. The event was created in partnership between the American Academy of Ophthalmology (AAO) and the American Society of Cataract and Refractive Surgery (ASCRS) and occurs the day prior to the American Academy of Ophthalmology (AAO) 2021 Annual Meeting. For more information, visit www.eyecelerator.com.

About Opus Genetics
Opus Genetics is a groundbreaking gene therapy company for inherited retinal diseases with a unique model and purpose. Backed by Foundation Fighting Blindness’s venture arm, the RD Fund, Opus combines unparalleled insight and commitment to patient need with wholly owned programs in numerous orphan retinal diseases. Its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. Based in Raleigh, N.C., the company leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. For more information, visit www.opusgenetics.com.

Media contact:
Heather Anderson
919-827-5539
handerson@6degreespr.com

Dr. Ash Jayagopal named Chief Scientific Officer
Mr. Joe Schachle appointed Chief Operating Officer

RALEIGH, N.C., Oct. 20, 2021 (GLOBE NEWSWIRE) — Opus Genetics, a patient-focused gene therapy company developing treatments for orphan inherited retinal diseases, today announced two key appointments to its founding executive team. Ash Jayagopal, Ph.D., has joined the company as Chief Scientific Officer (CSO) and Joe Schachle has joined as Chief Operating Officer (COO).

“We were thrilled to launch Opus last month to advance an AAV-based gene therapy portfolio to treat neglected, orphan inherited retinal diseases, and we welcome Ash and Joe’s leadership at this important and foundational time for the Company,” said Ben Yerxa, Ph.D., CEO of the Foundation Fighting Blindness and the Retinal Degeneration Fund, and acting CEO of Opus. “Ash’s career discovering and developing therapies for ocular diseases makes him well-suited for the role of Opus CSO, where he will be instrumental in the advancement of our initial programs OPGx-001 and OPGx-002 for Leber congenital amaurosis. Additionally, Joe brings deep operational experience to his role as COO, specifically his expertise in strategic planning, business development and operations, which will be invaluable as we build our company and create novel orphan manufacturing scale and efficiencies.”

Dr. Jayagopal has more than 13 years of experience in drug development, drug delivery platforms and biomarker development for retinal diseases. Prior to joining Opus, Dr. Jayagopal served as the executive director of discovery medicine at Kodiak Sciences, where he led the drug discovery team and shaped the strategy for leveraging Kodiak’s biopolymer technology for delivery of large and small molecules in retinal diseases. Previously, Dr. Jayagopal was head of molecular pharmacology and biomarkers in ophthalmology at Roche, where he built and led a team of more than 25 scientists focused on the discovery and validation of biologics, small molecules, and gene therapies for ocular diseases, including inherited retinal diseases. Dr. Jayagopal has also served as an assistant professor in the departments of ophthalmology and visual sciences at the Vanderbilt Eye Institute, and the departments of molecular physiology and biophysics of Vanderbilt University Medical Center.

“Opus was formed to bring an unprecedented combination of resources, elite science and the expertise of pioneers in ocular gene therapy to bear and drive transformative treatments to patients,” said Dr. Jayagopal. “With its advanced pipeline – unique for a company at this stage – Opus has the potential to be clinical-stage in the near-term, and I look forward to working with the team to break new scientific ground in the pursuit of better treatments for inherited retinal diseases.”

Mr. Schachle brings more than 30 years of experience in life sciences to Opus, with specific expertise in strategic and operational planning, business development, marketing and sales, and business intelligence. Before joining Opus, Mr. Schachle served as vice president of Customer Experience Enablement and vice president of global commercial services and controlling at Grifols, where he led multiple commercial departments across business units, managed key cross-divisional initiatives and directed strategic brand planning process. Previously, Mr. Schachle was the COO for Parion Sciences, and part of the team that secured partners for the company’s lead programs, which exceeded $1 billion in deal value. Mr. Schachle has also served as chief commercial officer for Inspire Pharmaceuticals, where he oversaw multiple partnering deals and promoted three eye care brands, including Restasis®. In addition, he’s held multiple sales and marketing leadership positions at GlaxoSmithKline, where he managed several billion-dollar brands including Advair®, Imitrex®, Wellbutrin SR®, Epivir® / Retrovir® and Combivir®.

“Opus is built by and for patients to efficiently move validated science toward patients leveraging scalable, strategic manufacturing and processes,” said Mr. Schachle. “I look forward to leading the work to operationalize this first-of-its-kind model to address significant unmet need in the treatment of neglected, orphan inherited retinal diseases.”

Dr. Jayagopal holds a Ph.D. in biomedical engineering from Vanderbilt University and an MBA from the Kelley School of Business, Indiana University. Mr. Schachle holds a B.A. in business administration from James Madison University and an MBA from Old Dominion University.

About Opus Genetics
Opus Genetics is a groundbreaking gene therapy company for inherited retinal diseases with a unique model and purpose. Backed by Foundation Fighting Blindness’s venture arm, the RD Fund, Opus combines unparalleled insight and commitment to patient need with wholly owned programs in numerous orphan retinal diseases. Its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. Based in Raleigh, N.C., the company leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. For more information, visit www.opusgenetics.com.

Media contact:
Heather Anderson
919-827-5539
handerson@6degreespr.com